Tenderkart now works inside Claude and ChatGPT: search and analyse tenders right from your chat
Loading…
Ref. No.
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
| # | Schedule | Awardee / L1 Bidder | Status | Bids | Value |
|---|---|---|---|---|---|
| 1 | Schedule 1 | LINK BIOTECH | Awarded | 1 | ₹1,465.55 |
| 2 | Schedule 2 | KESHRI NANDAN INDUSTRIES | Awarded | 1 | ₹5,400 |
| 3 | Schedule 3 | KESHRI NANDAN INDUSTRIES | Awarded | 1 | ₹6,000 |
| 4 | Schedule 4 | KESHRI NANDAN INDUSTRIES | Awarded | 1 | ₹4,500 |
| 5 | Schedule 5 | LINK BIOTECH | Awarded | 1 | ₹2,327 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
13 Feb 2025, 4:00 pmClosed
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
Paclitaxel
Apigenin
Epigallocatechin
Rutin
Mangiferin
7407434
GEM/2025/B/5847416
Two Packet Bid
Apigenin
GeM Contract
21 days
West Bengal; 24 Paraganas North
Item wise evaluation
BOQ
Awarded to KESHRI NANDAN INDUSTRIES
₹4,500
| Product | Brand / Model | HSN | Quantity | Unit Price | Amount |
|---|---|---|---|---|---|
| Rutin | Targetmol / T0795 | HSN not specified by seller | 50 mg | 90 | 4,500 |
Awarded to KESHRI NANDAN INDUSTRIES
₹6,000
| Product | Brand / Model | HSN | Quantity | Unit Price | Amount |
|---|---|---|---|---|---|
| Epigallocatechin | Targetmol / T2987 | HSN not specified by seller | 20 mg | 300 | 6,000 |
Awarded to LINK BIOTECH
₹1,465.55
| Product | Brand / Model | HSN | Quantity | Unit Price | Amount |
|---|---|---|---|---|---|
| Paclitaxel | Otto Chemie Pvt. Ltd. / P 1188 | 2932 | 5 mg | 293.11 | 1,465.55 |
Awarded to KESHRI NANDAN INDUSTRIES
₹5,400
| Product | Brand / Model | HSN | Quantity | Unit Price | Amount |
|---|---|---|---|---|---|
| Apigenin | Targetmol / T2175 | HSN not specified by seller | 25 mg | 216 | 5,400 |
Awarded to LINK BIOTECH
₹2,327
| Product | Brand / Model | HSN | Quantity | Unit Price | Amount |
|---|---|---|---|---|---|
| Mangiferin | BLD Pharma / BD33735 | 2933 | 10 mg | 232.7 | 2,327 |
11 documents required · 11 mandatory
3 yrs
₹31
10%
Exempted
22 Feb 2025
23 Jan 2025
13 Feb 2025
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|---|
| 1 | Paclitaxel | As per attached specification | 5 | mg | Malayamarutham Kalyan Kumar Raju 700091,4 CN BLOCK, SECTOR 5 | 21 |
| 2 | Apigenin | As per attached specification | 25 | mg | Malayamarutham Kalyan Kumar Raju 700091,4 CN BLOCK, SECTOR 5 | 21 |
| 3 | Epigallocatechin | As per attached specification | 20 | mg | Malayamarutham Kalyan Kumar Raju 700091,4 CN BLOCK, SECTOR 5 | 21 |
| 4 | Rutin | As per attached specification | 50 | mg | Malayamarutham Kalyan Kumar Raju 700091,4 CN BLOCK, SECTOR 5 | 21 |
| 5 | Mangiferin | As per attached specification | 10 | mg | Malayamarutham Kalyan Kumar Raju 700091,4 CN BLOCK, SECTOR 5 | 21 |
contract_GEMC-511687762241292.pdf
GeM contract · Paid plans only
contract_GEMC-511687743828696.pdf
GeM contract · Paid plans only
contract_GEMC-511687730211304.pdf
GeM contract · Paid plans only
contract_GEMC-511687741038272.pdf
GeM contract · Paid plans only
contract_GEMC-511687734137137.pdf
GeM contract · Paid plans only
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7407434.pdf
GEM_BID
attachment_file-_adulteration_2025-01-21-13-46-07_95b685f0177edc5c1b4ad4d3a16d6b0e.pdf
BOQ
boq_doc_sample_file_-_adulteration_2025-01-21-13-46-07_2a9e304742202fe202c2a932f851000f.csv
BOQ
atcadlt_85083581-f9e1-409e-93af1737623712183_aro3-cari.docx
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .